Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. (Q34561518)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C P Reynolds

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Min H Kang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Richard B Lock

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Malcolm A Smith

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

11

Peter J Houghton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

4

John M Maris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

10

Raushan T Kurmasheva

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2

E Anders Kolb

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

3

Stephen T Keir

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

7

Hernan Carol

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

9

Catherine A Billups

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

19 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

published in

Pediatric Blood Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

158-164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

7 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Initial testing of topotecan by the pediatric preclinical testing program.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Functional genome screen for therapeutic targets of osteosarcoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4241497

Targeting polo-like kinase 1 for cancer therapy.

7 July 2018

1 reference

Expression patterns of polo-like kinase 1 in human gastric cancer.

21 January 2018

1 reference

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.

21 January 2018

1 reference

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.24616

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

release_b73xmlne5bhilkl5zlzeyjvdl4

7 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b73xmlne5bhilkl5zlzeyjvdl4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956067%20AND%20SRC:MED&resulttype=core&format=json